Display options
Cite
Zolotukhin I, Luo D, Gorbatyuk O, et al. Improved Adeno-associated Viral Gene Transfer to Murine Glioma. J Genet Syndr Gene Ther. 2013;4(133)doi: 10.4172/2157-7412.1000133.
Zolotukhin, I., Luo, D., Gorbatyuk, O., Hoffman, B., Warrington, K., Herzog, R., Harrison, J., & Cao, O. (2013). Improved Adeno-associated Viral Gene Transfer to Murine Glioma. Journal of genetic syndromes & gene therapy, 4(133), . https://doi.org/10.4172/2157-7412.1000133
Zolotukhin, I, et al. "Improved Adeno-associated Viral Gene Transfer to Murine Glioma." Journal of genetic syndromes & gene therapy vol. 4,133 (2013). doi: https://doi.org/10.4172/2157-7412.1000133
Zolotukhin I, Luo D, Gorbatyuk O, Hoffman B, Warrington K, Herzog R, Harrison J, Cao O. Improved Adeno-associated Viral Gene Transfer to Murine Glioma. J Genet Syndr Gene Ther. 2013 Apr 29;4(133). doi: 10.4172/2157-7412.1000133. PMID: 24319629; PMCID: PMC3852404.
Copy Download .nbib Format: NLM
Share it on

J Genet Syndr Gene Ther. 2013 Apr 29;4(133). doi: 10.4172/2157-7412.1000133.

Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

Journal of genetic syndromes & gene therapy

I Zolotukhin, D Luo, Os Gorbatyuk, Be Hoffman, Kh Warrington, Rw Herzog, Jk Harrison, O Cao

Affiliations

  1. Department of Pediatrics, University of Florida, Gainesville, FL, USA.

PMID: 24319629 PMCID: PMC3852404 DOI: 10.4172/2157-7412.1000133

Abstract

Glioblastoma (GBM) is a deadly primary brain tumor. Current treatment, consisting of surgical removal of the tumor mass followed by chemotherapy and/or radiotherapy, does not significantly prolong survival. Gene therapies for GBM are being developed in clinical trials, for example using adenoviral vectors. While adeno-associated virus (AAV) represents an alternative vector system, limited gene transfer to glioma cells has hampered its use. Here, we evaluated newly emerged variants of AAV capsid for gene delivery to murine glioma. We tested a mutant AAV2 capsid devoid of 3 surface-exposed tyrosine residues, AAV2 (Y444-500-730F), and a "shuffed" capsid (ShH19, containing sequences from several serotypes) that had previously been selected for enhanced glial gene delivery. AAV2 (Y-F) and ShH19 showed improved transduction of murine glioma GL261 cells

Keywords: AAV; CNS; Cancer; Gene transfer; Glioma

References

  1. Gene Ther. 1998 Feb;5(2):166-73 - PubMed
  2. Mol Ther. 2009 Dec;17(12):2088-95 - PubMed
  3. Nat Med. 1996 Dec;2(12):1316-21 - PubMed
  4. Gene Ther. 2003 Apr;10(8):657-67 - PubMed
  5. J Gene Med. 2006 Sep;8(9):1131-40 - PubMed
  6. Neoplasia. 2001 May-Jun;3(3):255-63 - PubMed
  7. J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):213-22 - PubMed
  8. J Genet Syndr Gene Ther. 2012 Jan 18;1:1-9 - PubMed
  9. Mol Ther. 2011 Aug;19(8):1440-8 - PubMed
  10. Mol Ther. 2010 Dec;18(12):2048-56 - PubMed
  11. J Neurosurg. 2004 Feb;100(2):310-9 - PubMed
  12. Cancer Res. 1998 Dec 1;58(23):5275-9 - PubMed
  13. Mol Ther. 2005 Oct;12(4):585-98 - PubMed
  14. J Gen Virol. 2012 Oct;93(Pt 10):2131-2141 - PubMed
  15. Gene Ther. 1996 Nov;3(11):957-64 - PubMed
  16. Hum Gene Ther. 1998 May 20;9(8):1181-6 - PubMed
  17. Sci Transl Med. 2012 May 16;4(134):134ra61 - PubMed
  18. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14443-8 - PubMed
  19. Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7827-32 - PubMed
  20. Neurosci Lett. 2012 Oct 11;527(2):71-7 - PubMed
  21. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6 - PubMed
  22. J Neurooncol. 2000 Oct-Nov;50(1-2):149-63 - PubMed
  23. Hum Gene Ther. 2005 Mar;16(3):381-92 - PubMed
  24. Mol Ther. 2003 Dec;8(6):911-7 - PubMed
  25. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3428-32 - PubMed
  26. Hum Gene Ther. 2010 Nov;21(11):1527-43 - PubMed
  27. J Neuroimmunol. 2008 Jul 31;198(1-2):98-105 - PubMed
  28. J Neurooncol. 2000;46(2):115-23 - PubMed
  29. Cancer Res. 2008 May 1;68(9):3286-94 - PubMed
  30. J Gene Med. 2000 May-Jun;2(3):148-64 - PubMed
  31. J Genet Syndr Gene Ther. 2012 Oct 22;2012(3): - PubMed
  32. Cancer Gene Ther. 2002 Jan;9(1):9-15 - PubMed
  33. Mol Ther. 2011 Oct;19(10):1793-801 - PubMed
  34. Hum Gene Ther. 2002 Jun 10;13(9):1115-25 - PubMed
  35. J Genet Syndr Gene Ther. 2012 Aug 15;S1: - PubMed
  36. Cancer Res. 1995 Nov 1;55(21):4808-12 - PubMed
  37. Cancer Res. 2006 Aug 1;66(15):7429-37 - PubMed
  38. Cancer Gene Ther. 2006 Jan 1;13(1):99-106 - PubMed
  39. Cancer Gene Ther. 2003 May;10(5):353-64 - PubMed
  40. J Neurooncol. 2010 Feb;96(3):337-47 - PubMed
  41. Curr Gene Ther. 2011 Jun;11(3):155-80 - PubMed
  42. Jpn J Cancer Res. 1998 Jan;89(1):76-80 - PubMed
  43. Genes Dev. 2009 Jun 1;23(11):1327-37 - PubMed
  44. Cancer Res. 2005 Aug 15;65(16):7194-204 - PubMed
  45. Gene Ther. 2004 Nov;11(21):1551-8 - PubMed
  46. Mol Ther. 2009 Mar;17(3):463-71 - PubMed
  47. Hum Gene Ther. 2005 Jul;16(7):781-91 - PubMed
  48. Nat Genet. 2000 Sep;26(1):109-13 - PubMed
  49. Mol Ther. 2008 Oct;16(10):1648-56 - PubMed
  50. Cancer Gene Ther. 2009 Aug;16(8):664-71 - PubMed
  51. Blood. 2013 Mar 21;121(12):2224-33 - PubMed
  52. N Engl J Med. 2011 Dec 22;365(25):2357-65 - PubMed
  53. Neurol Res. 1995 Jun;17(3):209-16 - PubMed
  54. Mol Ther. 2013 Mar;21(3):509-19 - PubMed
  55. J Genet Syndr Gene Ther. 2012 Jan 10;S1: - PubMed
  56. Jpn J Cancer Res. 2002 Feb;93(2):223-8 - PubMed
  57. Mol Genet Metab. 2001 Sep-Oct;74(1-2):120-7 - PubMed
  58. Discov Med. 2010 Oct;10(53):293-304 - PubMed
  59. Brain Res Brain Res Protoc. 2004 Nov;14(1):18-24 - PubMed
  60. Mol Cell Biol. 2000 Jun;20(11):4106-14 - PubMed
  61. Gene Ther. 1999 Jun;6(6):973-85 - PubMed

Publication Types

Grant support